title: Paclitaxel-carboplatin chemotherapy does not cause encephalopathy in patients with ovarian cancer: a prospective EEG mapping study in 28 patients.
abstract: BACKGROUND
  The objective of this study was to evaluate possible effects of a paclitaxel containing chemotherapy, on the central nervous system (CNS) in women with ovarian cancer.
  
  
  METHODS
  Twenty-eight women with histologically documented epithelial ovarian carcinoma and treated with a combination chemotherapy consisting of paclitaxel and carboplatin entered the study. Patients were tested with resting EEG (R-EEG) before and after chemotherapy.
  
  
  RESULTS
  Twenty of the 28 patients responded to the chemotherapy (71%). Eleven patients (39%) developed peripheral neurotoxicity. A decrease of beta power and an increase of delta and theta power as well as a deceleration of the total centroid frequency clearly demonstrated a reduced vigilance in patients with ovarian cancer compared to healthy controls. On the other hand, the observed increase of beta power, a decrease of delta and theta power, and an acceleration of the total centroid from pre- to post-treatment demonstrated an improvement of vigilance in patients with ovarian cancer after treatment with paclitaxel/carboplatin.
  
  
  CONCLUSIONS
  The results of this study suggest that chemotherapy consisting of paclitaxel and carboplatin does not cause adverse effects on the central nervous system. Improved vigilance was measured in patients with ovarian cancer after chemotherapy.
authors: Department of Gynecology & Obstetrics, University of Vienna Medical School, A-1090 Vienna, Wahringer Gurtel 18-20, Austria.
authors: K
authors: K
authors: Mayerhofer
authors: K
authors: K
authors: Bodner
authors: B
authors: B
authors: Saletu
authors: B
authors: B
authors: Bodner-Adler
authors: P
authors: P
authors: Anderer
authors: L
authors: L
authors: Hefler
authors: M
authors: M
authors: Schindl
authors: A
authors: A
authors: Kaider
authors: S
authors: S
authors: Leodolter
authors: C
authors: C
authors: Kainz
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000523:psychology; D018262:Adenocarcinoma, Clear Cell / Q000188:drug therapy / Q000523:psychology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001927:Brain Diseases / Q000139:chemically induced*; D001931:Brain Mapping; D016190:Carboplatin / Q000009:adverse effects / Q000627:therapeutic use; D018269:Carcinoma, Endometrioid / Q000188:drug therapy / Q000523:psychology; D003072:Cognition Disorders / Q000139:chemically induced; D003907:Dexamethasone / Q000008:administration & dosage; D004569:Electroencephalography / Q000187:drug effects*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000523:psychology; D017239:Paclitaxel / Q000009:adverse effects / Q000627:therapeutic use; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D011446:Prospective Studies
chemical_list: D003907:Dexamethasone; D016190:Carboplatin; D017239:Paclitaxel